Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Studies of liver transplant patients off anti-rejection drugs have altered cell profile

03.06.2003


University of Pittsburgh researchers report results in American Journal of Transplantation and at American Transplant Congress, suggesting blood test to determine who can be weaned not far off



Liver transplant patients who are off all immunosuppression and those who are undergoing withdrawal of their anti-rejection drugs have higher concentrations of a special immune system cell than those patients who have failed attempts at weaning or who have a history of organ rejection, report University of Pittsburgh researchers. Those off drugs have the same cellular profile as normal, healthy volunteers, who the researchers also studied.

Results of the study are published in the June issue of the American Journal of Transplantation and are being presented today at the American Transplant Congress, the joint scientific meeting of the American Society of Transplant Surgeons and the American Society of Transplantation running through June 4 at the Marriott Wardman Park Hotel in Washington, D.C.


The researchers hope the findings will bring them one step closer to developing a simple blood test predictive of transplant tolerance – the immune system’s full acceptance of a transplanted organ – and of which patients can be successfully weaned off all drugs. However, the researchers caution that further studies will be needed to verify their results.

"Developing such a test or series of tests would be of considerable value in identifying those patients who might be safely weaned off anti-rejection therapy. Our finding a higher incidence of a subtype of a certain dendritic cell in our weaned and nearly weaned patients is a positive step toward this goal," said lead author George Mazariegos, M.D., associate professor of surgery at the Thomas E. Starzl Transplantation Institute and the University of Pittsburgh School of Medicine.

Looking for the presence of different kinds of dendritic cells, the researchers found that patients off all anti-rejection drugs and those in the process of drug withdrawal had significantly more of a beneficial kind of dendritic cell and fewer numbers of the more harmful dendritic cells, a cellular profile that was similar to normal, healthy non-transplant patients who served as a control group. Compared to those who required daily doses of anti-rejection drugs – those who failed at being weaned or who had a history of rejection episodes – the patients off drugs or nearing that target also had a much higher ratio of the good cells to bad cells.

These so-called beneficial dendritic cells are immature or precursor dendritic cells that derive from plasmacytoid T cells (pDC2). While dendritic cells, a rare type of white blood cell that is present in all tissues, are usually known for their ability to identify and present antigens, or foreign substances, to other immune system cells that are programmed to destroy the antigen, not until recently did researchers identify subtypes like the pDC2 that have the opposite effect. These appear to regulate the immune response and determine that a frontline attack against the organ by T cells is unwarranted. "It is quite exciting to identify the presence of this dendritic cell subtype, which we have noted in laboratory models, in patients who by virtue of their being off immunosuppression are tolerant of their transplanted organs," stated Angus Thomson, Ph.D., D.Sc., professor of surgery and immunology at the Thomas E. Starzl Transplantation Institute and University of Pittsburgh School of Medicine, and senior author.

The published pilot study involved six patients who had been weaned for a mean of 3.3 years, the longest for nearly eight years. Of these, two had been weaned through a physician-controlled protocol, three were taken off the drugs because of serious infectious disease concerns, and one patient had stopped taking the drugs on his own. A second group of patients consisted of 23 patients undergoing the weaning process, and the third group was comprised of 11 patients taking maintenance doses of immunosuppression. Six of these 11 had failed at weaning and five had a history of rejection episodes. Thirteen healthy non-transplant patients served as controls.

At ATC, Dr. Mazariegos is reporting update results that were obtained in eight weaned patients, 26 patients in the process of being weaned and 16 patients who required maintenance immunosuppression. Of the weaned patients, three were taken off for emergent reasons, three were weaned through the protocol and two were noncompliant patients who stopped on their own.

According to the authors, their findings involving dendritic cells, and those published by the team last year that looked at genetic profiles of key regulatory proteins that regulate the immune system, are the first to definitively give clues to the make-up of patients who are able to be off all immunosuppression.

"While the initial results indicate there may be some correlation with the presence of ’good dendritic cells’ and immune unresponsiveness, a longer, more complete investigation must now be performed if these cells are to be validated as a surrogate marker of tolerance," said Terry Strom, M.D., co-chair of the Immune Tolerance Network (ITN) Assay Group.

To determine the validity of the dendritic cell profile as a possible test to predict successful weaning, the researchers plan to examine a larger group of liver transplant patients in whom weaning is being considered.

Typically, a life-long regimen of anti-rejection drugs is required to prevent the transplanted organ from being attacked by the patient’s immune system. Such drugs can cause serious complications, such as tumor growth, and make patients more susceptible to infections. The risks associated with long-term immunosuppressive therapies are one of the key limiting factors of successful organ transplantation.

This study was performed as a project of the ITN, a seven-year clinical research project headquartered at the University of California, San Francisco and supported by the National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases and the Juvenile Diabetes Research Foundation.

Dr. Thomson is principal investigator of the Pittsburgh-based ITN study and Dr. Mazariegos is a co-investigator. Other researchers include Adriana Zeevi, Ph.D., co-principal investigator, and Jorge Reyes, M.D., a co-investigator.


CONTACT:
Lisa Rossi (cell 412-916-3315)
Michele Baum
PHONE: 412-647-3555
FAX: 412-624-3184
E-MAIL:
RossiL@upmc.edu
BaumMD@upmc.edu

Lisa Rossi | EurekAlert!
Further information:
http://www.upmc.edu/

More articles from Health and Medicine:

nachricht Routing gene therapy directly into the brain
07.12.2017 | Boston Children's Hospital

nachricht New Hope for Cancer Therapies: Targeted Monitoring may help Improve Tumor Treatment
01.12.2017 | Berliner Institut für Gesundheitsforschung / Berlin Institute of Health (BIH)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

Im Focus: Successful Mechanical Testing of Nanowires

With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong

Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...

Im Focus: Virtual Reality for Bacteria

An interdisciplinary group of researchers interfaced individual bacteria with a computer to build a hybrid bio-digital circuit - Study published in Nature Communications

Scientists at the Institute of Science and Technology Austria (IST Austria) have managed to control the behavior of individual bacteria by connecting them to a...

Im Focus: A space-time sensor for light-matter interactions

Physicists in the Laboratory for Attosecond Physics (run jointly by LMU Munich and the Max Planck Institute for Quantum Optics) have developed an attosecond electron microscope that allows them to visualize the dispersion of light in time and space, and observe the motions of electrons in atoms.

The most basic of all physical interactions in nature is that between light and matter. This interaction takes place in attosecond times (i.e. billionths of a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Midwife and signpost for photons

11.12.2017 | Physics and Astronomy

How do megacities impact coastal seas? Searching for evidence in Chinese marginal seas

11.12.2017 | Earth Sciences

PhoxTroT: Optical Interconnect Technologies Revolutionized Data Centers and HPC Systems

11.12.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>